|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
NL1003648C2
(nl)
|
1996-07-19 |
1998-01-21 |
Carino Cornelis Sunderman |
Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
|
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
|
ES2279585T3
(es)
|
1997-09-23 |
2007-08-16 |
Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts |
Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
|
|
DK1212422T3
(da)
|
1999-08-24 |
2007-07-02 |
Medarex Inc |
Humane CTLA-4-antistoffer og anvendelserne deraf
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
TWI263496B
(en)
|
1999-12-10 |
2006-10-11 |
Novartis Ag |
Pharmaceutical combinations and their use in treating gastrointestinal disorders
|
|
US6579243B2
(en)
*
|
2000-03-02 |
2003-06-17 |
Scimed Life Systems, Inc. |
Catheter with thermal sensor for detection of vulnerable plaque
|
|
MXPA02010011A
(es)
|
2000-04-11 |
2003-04-25 |
Genentech Inc |
Anticuerpos multivalentes y usos para los mismos.
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
|
US7794710B2
(en)
*
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
US20030124149A1
(en)
|
2001-07-06 |
2003-07-03 |
Shalaby Shalaby W. |
Bioactive absorbable microparticles as therapeutic vaccines
|
|
WO2003039592A2
(de)
|
2001-11-09 |
2003-05-15 |
Medigene Aktiengesellschaft |
Zelluläre impfstoffe mit adjuvanzien
|
|
ATE481985T1
(de)
|
2002-07-03 |
2010-10-15 |
Ono Pharmaceutical Co |
Immunpotenzierende zusammensetzungen
|
|
AU2005229009A1
(en)
|
2004-03-23 |
2005-10-13 |
Amgen, Inc. |
Monoclonal antibodies specific for human OX40L (CD 134L)
|
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
|
CA2572684A1
(en)
|
2004-06-29 |
2006-01-12 |
The Johns Hopkins University |
Amelioration of drug-induced toxicity
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
WO2006042237A2
(en)
|
2004-10-06 |
2006-04-20 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
|
KR101498834B1
(ko)
*
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
|
PL2397156T3
(pl)
|
2005-06-08 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1)
|
|
HRP20080053A2
(hr)
|
2005-07-01 |
2009-08-31 |
Medarex |
Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
|
|
BRPI0621065A2
(pt)
|
2005-12-16 |
2011-11-29 |
Genentech Inc |
anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
WO2008083174A2
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
CN101861168B
(zh)
|
2007-05-07 |
2014-07-02 |
米迪缪尼有限公司 |
抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
|
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
PL3208612T3
(pl)
|
2008-04-09 |
2020-03-31 |
Genentech, Inc. |
Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
|
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
|
EP3133086B1
(en)
|
2008-09-26 |
2018-08-01 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
|
|
WO2010056804A1
(en)
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
|
CA3120172A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
PT2564695E
(pt)
|
2009-07-08 |
2015-06-03 |
Kymab Ltd |
Modelos animais e moléculas terapêuticas
|
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
CN104826106B
(zh)
|
2009-09-30 |
2019-01-11 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
HUE037159T2
(hu)
|
2009-11-24 |
2018-08-28 |
Medimmune Ltd |
Targetált kötõdõ ágensek B7-H1 ellen
|
|
AU2010328347B2
(en)
|
2009-12-07 |
2015-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
|
EP2513145B1
(en)
|
2009-12-14 |
2018-01-24 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
CN103228130B
(zh)
|
2010-06-17 |
2016-03-16 |
科马布有限公司 |
动物模型及治疗分子
|
|
EP3147297B1
(en)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies directed against icos and uses thereof
|
|
EP3403672A1
(en)
|
2011-04-20 |
2018-11-21 |
Medlmmune, LLC |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
CA2841416A1
(en)
|
2011-06-15 |
2012-12-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of selecting therapeutic indications
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
MX349096B
(es)
|
2011-11-28 |
2017-07-11 |
Merck Patent Gmbh |
Anticuerpos anti-pd-l1 y sus usos.
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳－法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
|
US20150322119A1
(en)
|
2012-12-03 |
2015-11-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
PL2970473T3
(pl)
|
2013-03-14 |
2018-01-31 |
Bristol Myers Squibb Co |
Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
|
|
FR3006774B1
(fr)
|
2013-06-10 |
2015-07-10 |
Univ Limoges |
Guide d'onde a coeur creux avec un contour optimise
|
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
|
CA2926856A1
(en)
|
2013-10-25 |
2015-04-30 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
BR112016015140A2
(pt)
|
2013-12-30 |
2018-01-23 |
Epimab Biotherapeutics Inc. |
imunoglobulina com fabs in-tandem e usos das mesmas
|
|
PT3094351T
(pt)
|
2014-01-15 |
2022-02-22 |
Kadmon Corp Llc |
Agentes imunomoduladores
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106687125B
(zh)
|
2014-03-12 |
2021-12-14 |
耶达研究与开发有限公司 |
降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
|
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
KR20230165876A
(ko)
|
2014-05-13 |
2023-12-05 |
메디뮨 리미티드 |
비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
EP3149042B1
(en)
|
2014-05-29 |
2019-08-28 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
|
KR102130600B1
(ko)
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
MY188940A
(en)
|
2014-07-11 |
2022-01-13 |
Ventana Med Syst Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
TN2017000024A1
(en)
|
2014-08-19 |
2018-07-04 |
Merck Sharp & Dohme |
Anti-tigit antibodies.
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
US10047138B1
(en)
|
2014-12-03 |
2018-08-14 |
Amgen Inc. |
Fusion protein, cells expressing the fusion protein, and uses thereof
|
|
MX389267B
(es)
|
2014-12-23 |
2025-03-20 |
Bristol Myers Squibb Co |
Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
SG10202001019TA
(en)
*
|
2015-03-23 |
2020-04-29 |
Jounce Therapeutics Inc |
Antibodies to icos
|
|
JP6936784B2
(ja)
|
2015-03-30 |
2021-09-22 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
EP3307777A4
(en)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
NOVEL ANTI-PD-L1 ANTIBODIES
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
CN108290936B
(zh)
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
JP6861418B2
(ja)
|
2015-09-02 |
2021-04-28 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
|
|
HUE069796T2
(hu)
|
2015-09-25 |
2025-04-28 |
Hoffmann La Roche |
Anti-TIGIT ellenanyagok és alkalmazásukra szolgáló eljárások
|
|
CA3000404A1
(en)
|
2015-10-01 |
2017-04-06 |
Potenza Therapeutics, Inc. |
Anti-tigit antigen-binding proteins and methods of use thereof
|
|
WO2017070423A1
(en)
|
2015-10-22 |
2017-04-27 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
|
US10544222B2
(en)
|
2015-11-18 |
2020-01-28 |
Merck Sharp & Dohme Corp. |
PD1/CTLA4 binders
|
|
WO2017213695A1
(en)
|
2016-06-07 |
2017-12-14 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
TW201803905A
(zh)
*
|
2016-06-20 |
2018-02-01 |
克馬伯有限公司 |
用於免疫腫瘤學之多重專一性抗體
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
|
KR102604433B1
(ko)
|
2016-08-09 |
2023-11-24 |
키맵 리미티드 |
항-icos 항체
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018047178A1
(en)
|
2016-09-10 |
2018-03-15 |
Yeda Research And Development Co. Ltd. |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
KR20190088480A
(ko)
|
2016-11-02 |
2019-07-26 |
조운스 테라퓨틱스, 인크. |
Pd-1에 대한 항체 및 그의 용도
|
|
EP3534947A1
(en)
*
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
US20200190191A1
(en)
*
|
2016-12-20 |
2020-06-18 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
US20200024351A1
(en)
|
2017-04-03 |
2020-01-23 |
Jounce Therapeutics, Inc. |
Compositions and Methods for the Treatment of Cancer
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
GB201709808D0
(en)
*
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
GB201721338D0
(en)
*
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
EP3728316B1
(en)
|
2017-12-19 |
2025-02-26 |
invoX Pharma Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
EP3728314A1
(en)
*
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB2583352B
(en)
|
2019-04-24 |
2023-09-06 |
Univ Southampton |
Antiresonant hollow core fibre, preform therefor and method of fabrication
|
|
CN110579836B
(zh)
|
2019-07-31 |
2020-10-02 |
江西师范大学 |
一种多谐振层空芯光纤
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
GB202107994D0
(en)
*
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|